

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com **https:**//www.wjgnet.com

CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS

Manuscript pa	age numl	er (With	out Figur	es):	12	Rate: 6.2 (CNY per	page
						Editing Fee: _	74.4	CNY
Figure count: _	4	_Figure 1	nandling	time:_	90	min_Rate: 1	CNY pe	r min
						Editing Fee:	90	CNY
	XML and	d PDF co	nverting	time <u>:</u>	50	min Rate: 1	CNY pe	r min
						Editing Fee:	50	CNY
				Manu	ıscrip	ot word count:	3044	
				٦	Γotal	Editing Fee: _	214.4	CNY
					Sci	ientific Editor: 9	Geng-Lo	ng Liu

Date of signature: ______(month/day/year)

		Comm
Item No.		ents
	Specific items for verification	Yes=[Y
]
		No=
		[N]
	General Information of the Manuscript	
	Name of journal: World Journal of Clinical Cases	
	Manuscript NO.: 79415	
1	Column: Case Report	[]/]
1	Title: Langerhans cell histiocytosis involving only the thymus in an adult: A	[Y]
	case report	
	Authors: Yi-Fan Li, Shao-Hui Han, Peng Qie, Qi-Fan Yin and Hui-En Wang	
	Reviewer code: 03728868, and 06275221	



Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

	First decision: 2022-09-05 09:27
	Editorial Office's Comments
	Science Editor: Dear Hui-En Wang First of all, thank you very much for your
	trust in selecting the World Journal of Clinical Cases under Baishideng
	Publishing Group(BPG) to submit the manuscript. We have received your
	revised manuscript (Langerhans cell histiocytosis involving only the thymus in
	an adult: A case report) (NO.:79415). However, in checking the manuscript, we
	have found that there are still many inconformity with the format and technical
	requirements. 1 Figures We notice that Figure4 is a combination of two
	pictures in fact. Please mark A and B and explain them respectively. Note:
	Please provide the Figures cited in the original manuscript in the form of PPT.
	All text can be edited, including A,B, arrows, etc. All legends are incorrectly
2	formatted and require a general title and explanation for each figure. Such as
4	Figure 1 title. A: ; B: ; C: . 2 Provide new language certificate
	After our verification, we found that the language editing company
	mentioned in your submitted language certificate only polished the initial
	manuscript. Following the many changes that were introduced into the
	content of your manuscript during the revision process, some language
	problems exist in the revised manuscript. Further language polishing is
	required to fix all grammatical, syntactical, formatting and other related
	errors, in order to meet the publication requirement (Grade A). Please modify o
	n the basis of the attached manuscript.
	Now, you are requested to send the revised manuscript to a professional
	English language editing company or a native English-speaking expert to
	polish the language further. When you submit the subsequent polished



Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

manuscript to us, you must provide a new language certificate along with it. Once this step is completed, your manuscript will be quickly accepted and published online. Please visit the following website for the professional English language editing companies we recommend: https://www.wjgnet.com/bpg/gerinfo/240. Please provide and send them to us as soon as possible. If you have any questions, please timely contact us. Sincerely

Company Editor-in-Chief: I have reviewed the Peer-Review Report, full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Clinical Cases, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor. In order to respect and protect the author's intellectual property rights and prevent others from misappropriating figures without the author's authorization or abusing figures without indicating the source, we will indicate the author's copyright for figures originally generated by the author, and if the author has used a figure published elsewhere or that is copyrighted, the author needs to be authorized by the previous publisher or the copyright holder and/or indicate the reference source and copyrights. Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original', the author needs to add the following copyright information to the bottom right-hand



Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

	1	
	side of the picture in PowerPoint (PPT): Copyright ©The Author(s) 2022.	
	Before final acceptance, when revising the manuscript, the author must	
	supplement and improve the highlights of the latest cutting-edge research	
	results, thereby further improving the content of the manuscript. To this end,	
	authors are advised to apply a new tool, the RCA. RCA is an artificial	
	intelligence technology-based open multidisciplinary citation analysis	
	database. In it, upon obtaining search results from the keywords entered by the	
	author, "Impact Index Per Article" under "Ranked by" should be selected to	
	find the latest highlight articles, which can then be used to further improve an	
	article under preparation/peer-review/revision. Please visit our RCA database	
	for more information at: https://www.referencecitationanalysis.com/.	
3	The fixed headings are copied.	[Y]
	The title concisely summarizes the main topic of the study and is not too long	
4	(no more than 18 words). Words such as 'exploration', 'research', 'analysis',	D. C.
4	'observation', and 'investigation' are avoided. The title does not start with 'The'	[Y]
	and does not include any Arabic numbers or uncommon abbreviations.	
5	A short running title is provided (no more than 6 words).	[Y]
	The authors' full family (sur)names and full/abbreviated first names are listed	
6	on the title page and are consistent with those listed in the signed BPG	[Y]
	Copyright License Agreement form.	
	The 'Author contributions' passage describes the specific contribution(s) made	
	by each author. The author's names are listed in the following format: full	
	family (sur)name followed by abbreviated first and middles names.	
	e.g., "Wang CL and Liang L contributed equally to this work; Wang CL, Liang	D/I
7	L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL,	[Y]
	Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR	
	contributed new reagents and analytic tools; Wang CL, Liang L and Fu JF	
	analyzed the data; and Wang CL, Liang L and Fu JF wrote the manuscript. All	
-	-	



Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

	authors have read and approve the final manuscript."	
	The 'Supported by' statement describes the source(s) of financial support and	
8	includes the corresponding identification number(s) and program ID(s) if	[N]
	available, and contains no spelling errors.	
	The 'Corresponding author' passage provides the corresponding author's full	
9	first and family (sur)names, abbreviated title (e.g., MD, PhD), affiliated	[Y]
	institute's name and complete postal address (including zip code) and e-mail	
	(written in all lowercase), and contains no spelling errors.	
	The Manuscript Tracking information (i.e., Received, Peer review started, First	
10	decision, Revised, Accepted, Article in press, and Published online) are	[Y]
10	provided along with the corresponding editor and date for each item, and	[+]
	contain no spelling errors.	
	The Abstract section is formatted according to the article-specific style	
	(structured vs unstructured) and word count thresholds, as follows:	
	Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview,	
	Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract	
11	that is no less than 200 words.	[3/]
11	Field of Vision, Case Report and Letter to the Editor: Non-structured abstract	[Y]
	that is no less than 150 words.	
	Research articles: Structured abstract with subsections for AIM (no more than	
	20 words); METHODS (no less than 80 words); RESULTS (no less than 120	
	words); and CONCLUSION (no more than 26 words).	



Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

	The 'Key words' list provides 5-10 keywords that reflect the main content of	
12	the study. The first letter of each keyword is capitalized, and each keyword is	[Y]
	separated by a semicolon.	
	The "citation" contains authors' names and manuscript title. The name of the	
	first author should be typed in bold letters; the family (sur) name of all authors	
	should be typed with the first letter capitalized, followed by their abbreviated	
10	first and middle initials. For example, an article by Jae Moon Yoon, Ki Young	D/1
13	Son, Chun Sick Eom, Daniel Durrance, Sang Min Park will be written as Yoon	[Y]
	JM, Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes mellitus	
	increases the risk of gastric cancer: A meta-analysis. World J Gastroenterol 2019;	
	In press	
	The 'Core tip' provides a summary (less than 100 words) of the study that	
14	outlines the most innovative and important arguments and core contents of the	[Y]
	paper and will serve to effectively attract readers.	
	The 'INTRODUCTION' section clearly describes the relevant background	
	information for the study. Only the most relevant and current (within the past	
	5 years) literature is cited, with the exception of rare instances of seminal	
	literature citations. All technical terms and/or abbreviations are explained	
15	and/or defined, with the full name of abbreviations given upon first	[V]
15	appearance in the text and the abbreviation presented in parentheses [i.e.,	[Y]
	"computed tomography (CT)"]. First-person pronouns (e.g., 'I', 'we') are used	
	appropriately to clearly indicate the work performed by the author(s). When	
	weaknesses of previous studies are described in the text to highlight the	
	innovations related to the current study, the information is presented carefully.	
	The 'MATERIALS AND METHODS' section clearly and accurately describes	
16	all materials and methods used to obtain the data presented in the article and is	[N]
	adequate for a reader to repeat the study.	



Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

	The 'RESULTS' section concisely describes the observational and experimental	
	results. Representative data and data that have scientific significance are	
17	emphasized. Data is presented in either the text, a table or figure (i.e., chart,	[N]
1/	diagram, graph or image), but is not repeated among each. Information	[1]
	presented in the tables and figures clearly describes the trends, meaning, and	
	inferences. Results described in textual form are accurate, concise and clear.	
	Statistical symbols are accurate. Statistical significance is expressed as ${}^{a}P$ < 0.05,	
	^{b}P < 0.01 (P > 0.05 usually does not need to be denoted). If there are other series	
18	of P values, ^{c}P < 0.05 and ^{d}P < 0.01 are used, and a third series of P values is	[N]
	expressed as $^{\rm e}P$ < 0.05 and $^{\rm f}P$ < 0.01. Statistical data is expressed as mean \pm SD	
	or mean ± SE.	
	The 'DISCUSSION' section (1) describes the main purpose and hypothesis of	
	the study; (2) summarizes the most important results; (3) illustrates and	
	explains the results (but does not simply repeat the data) and draws	
19	conclusions or inferences based on the results; (4) points out the limitations of	[Y]
	the study and their impact on the results, as well as proposes further advice on	
	future research topic(s) or direction(s); and (5) describes the theoretical	
	significance and practical value of the findings.	
	The 'ACKNOWLEDGEMENTS' section expresses gratitude to any individuals	
	or organizations for technical support (i.e., providing instrumentation,	
20	equipment or experimental materials, and/or assistance in experimental	[N]
	work), non-technical services (i.e., useful inspiration, suggestions, guidance, or	
	review), and/or any other auxiliary work.	
01	The 'ARTICLE HIGHLIGHTS' section provides comments for original articles	F5 * 3
21	in accordance with the specified format.	[N]



Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

	The 'REFERENCES' section lists the references in the Vancouver style. This	
	style uses Arabic numeral in-text citations based on the order of the first	
	appearance of a source in the text. For citations where the author's name is	
	indicated in the text, a superscript number should be placed following the	
	name (i.e, "Pang et al"). For citations where no author is indicated, a	
22	superscript number should be placed at the end of the sentence. Respective	[Y]
	examples are: "Ma ^[1] reported", "Pan et al ^[2-5] indicated"; "PCR has a	
	high sensitivity ^[6,9] ." No superscript numbers are used when the reference	
	number is described in the text; for example, "The experimental method used	
	has been described in reference [8]." The style of reference citations in tables is	
	the same as that in the text (e.g., Pan et $al^{[2-5]}$, please see reference [8]).	
	Journal references have been verified to ensure that there are no duplicate	
	references and that the PMID numbers are correct. For references not yet	
	included in PubMed: the name of Chinese journals is spelled out using Chinese	
23	Pinyin, with the first letter of each word capitalized (e.g., Shijie Huaren Xiaohua	[Y]
	Zazhi); the name of journals in other languages are listed according to indexing	
	information retrieved from Google. Book references are presented with all the	
	information relevant to the electronic version.	
	The number of cited references is appropriate for the article type, as follows:	
	Commentary: no less than 50;	
24	Review: no less than 100;	[Y]
	Article: no less than 30/26;	
	Case Report and Letter to the Editor: no less than 1.	
	The ethics-related statements are provided in accordance with the manuscript	
25	type (e.g., Manuscript NoInstitutional review board statement, Manuscript	[N]
	NoAnimal care and use statement, etc.).	
26	The names of the peer reviewers and the scientific editor are present at the end	[]/]
26	of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang JL).	[Y]
ı	-	



Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

The order and numerical labeling of tables and figures is consistent with their appearance and presentation in the text. Symbols in tables (e.g., +, -, ×, +, *) correctly correspond to the definitions in the footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:, B:, C:, D:, F: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s)); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers, e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement) (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use			
correctly correspond to the definitions in the footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		The order and numerical labeling of tables and figures is consistent with their	
provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The realed ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		appearance and presentation in the text. Symbols in tables (e.g., +, -, \times , \div , *)	
white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoBiostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		correctly correspond to the definitions in the footnotes. Only one legend is	
Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoBiostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval	27	provided for each multi-panel figure consisting of color graphs, black and	[Y]
treatment. A:; B:; C:; D:; E:; F: Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		white graphs, or line graphs that depicts data of the same theme. For example:	
Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		Figure 1 Pathological changes in atrophic gastritis tissue before and after	
including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s)); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		treatment. A:; B:; C:; D:; E:; F:	
amplification curves, and survival curves. The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		Split pictures include flow charts, line graphs, histograms, and graphs	D.T.
The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval	28	including text. Unsplit pictures include meta-analysis diagrams, PCR	[N]
peer-reviewers' comments. The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		amplification curves, and survival curves.	
The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval	20	The author(s) highlighted the changes made to the manuscript according to the	[1/]
made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870-Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoConflict-of-interest statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval	29	peer-reviewers' comments.	[1]
made to the manuscript. The revised manuscript is provided (file name: Manuscript NoReview; e.g., 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval	20	The responses to the peer-reviewers' comments are consistent with the changes	[V]
31 The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval	30	made to the manuscript.	[1]
The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		The revised manuscript is provided (file name: Manuscript NoReview; e.g.,	
NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoInstitutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		870- Review).	
NoPeer-review(s); e.g., 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval	31	The letter of peer-reviewers' comments is provided (file name: Manuscript	[V]
reviewers; e.g., 870-Answering reviewers). The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval	31	NoPeer-review(s); e.g., 870-Peer-review(s)).	[1]
The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		The response letter is provided (file name: Manuscript NoAnswering	
grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		reviewers; e.g., 870-Answering reviewers).	
(file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		The related ethics and relevant documents are provided, such as (1) Approved	
certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		grant application form(s) or funding agency copy of any approval document(s)	
Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		(file name: Manuscript NoGrant application form(s)); (2) Biostatistics review	
statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		certificate (file name: Manuscript NoBiostatistics statement); (3)	
statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval	32	Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest	[Y]
approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval		statement); (4) Clinical trial registration statement (file name: Manuscript	[+]
board statement); (6) Institutional animal care and use committee approval		NoClinical trial registration statement); (5) Institutional review board	
		approval form or document (file name: Manuscript NoInstitutional review	
form or document (file name: Manuscript NoInstitutional animal care and use		board statement); (6) Institutional animal care and use committee approval	
		form or document (file name: Manuscript NoInstitutional animal care and use	



Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

	committee statement), and (7) Signed informed consent form(s) or document(s)	
	(file name: Manuscript NoInformed consent statement).	
	All authors signed the BPG Copyright license agreement form (file name:	
33	Manuscript NoCopyright license agreement; e.g., 870-Copyright license	[Y]
	agreement).	
	The language certificate provided by authors who are non-native speakers of	
34	English meets the BPG requirements (file name: Manuscript NoLanguage	[Y]
	certificate; e.g., 870-Language certificate).	
	The photos licensed in the Agreement for Use of Personal Photos are consistent	
35	with those in the paper (file name: Manuscript NoAgreement for use of	[N]
	personal photos; e.g., 870-Agreement for use of personal photos).	
	This document (Checklist of Responsibilities for Scientific Editors) has been	
36	saved under the file name: manuscript NoScientific editor work list (e.g.,	[Y]
	870-Scientific editor work list).	
	A CrossCheck investigation (an effective tool for detecting unoriginal content,	
	enabling our editors to preserve the journal's integrity and the authors'	
	copyright) has been performed for the manuscript via the website:	
	http://www.ithenticate.com/. The results document contains the following	
37	information for the manuscript: "Name of journal", "Manuscript No.",	[Y]
01	"Columns", "Title" and "Author list". The Figure of the CrossCheck results is	[+]
	saved in JPEG format (.jpg) at 1440 × 680 pixel resolution. The PDF of the	
	CrossCheck results has been saved under the file name: manuscript No	
	CrossCheck report (e.g., 870-CrossCheck report). The Google searches have also	
	been performed to further ensure publication of original content.	
38	The text of the manuscript is typed in Book Antiqua font, 12 pt, with 1.5 line	[Y]
	spacing.	



Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

Responsib ilities of scientific editors

The primary responsibilities of our scientific editors include carefully checking the entire manuscript and all accompanying materials for: (1) errors in spelling, grammar, punctuation and wording; (2) suitability of tables, figures, figure data and legends; (3) accurate and appropriate presentation of symbols (e.g. +, -, ×, ÷, %, *) in tables and figures; and (4) complete and comprehensive revision of the manuscript according to the reviewers' comments.

Publicatio n process

Manuscript reception and registration→Initial review by scientific editor→Peer peer review→First round of meeting review→End of evaluation→To be accepted→Revision by the author(s)→Second round of meeting evaluation→To be accepted/revised/rejected→Final review by the Editor-in-Chief (final quality control for academic content and language quality)—Final acceptance and charging of publication fee→Language editing→Production→Proofreading by scientific editor→Proofreading by deputy editor→Final review by Editor-in-Chief→Release of online open-access papers in electronic form on the BPG website→Release of online papers on PubMed Central→Delivery of high-quality PDF reprints to the author(s)→End of the publication process.